Business
Novavax Nuvaxovid™ COVID-19 Vaccine Now Available in Israel for Individuals Aged 12 and Older
The Israeli Advisory Committee on Epidemics has recommended that Nuvaxovid™ be approved for ages 12 and older as a primary series and as a heterologous
About this update from Novavax, Inc.
[{"type":"text","content":"The Israeli Advisory Committee on Epidemics has recommended that Nuvaxovid™ be approved for ages 12 and older as a primary series and as a heterologous booster for those previously vaccinated with mRNA vaccines GAITHERSBURG, Md., Sept. 16, 2022 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that the Israel Ministry of Health has granted an import and use permit which provides individuals aged 12 and older access to the Nuvaxovid™ (NVX-CoV2373) COVID-19 vaccine for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as a primary series and as a heterologous booster for those previously vaccinated with mRNA vaccines. The permit is based on the Israeli Advisory Committee on Epidemics' recommendation.\n\"Today's milestone provides the people of Israel a protein-based COVID-19 vaccine developed using an innovative approach to traditional technology,\" said Stanley C. Erck, President and Chief Executive Officer, Novavax. \"Nuvaxovid is now available for use in Israel in individuals aged 12 and older as both a primary series and a booster regardless of previous vaccine history.\"\nNuvaxovid has received authorization for use in adults aged 18 and older from more than 40 markets, including the U.S. and from the World Health Organization. In the 12 through 17 year-old population, the vaccine has been authorized in more than 10 markets including the U.S., the European Union, and the United Kingdom. Nuvaxovid has also been authorized in the European Union, Japan, Australia, New Zealand, and Switzerland as a booster in adults aged 18 and older. The vaccine is actively under review in other markets.\nTrade Name in the U.S.The trade name Nuvaxovid™ has not yet been approved by the U.S. Food and Drug Administration.\nImportant Safety InformationNuvaxovid is contraindicated in persons who have a hypersensitivity to the active substance, or to any of the excipients.Events of anaphylaxis have been reported with administration of COVID-19 vaccines. Appropriate medical treatment and supervision should be available in case of an anaphylactic reaction following the administration of the vaccine. Close observation for at lea...